leadf
logo-loader
viewChampignon Brands Inc.

Champignon Brands appoints Jim Bailey, former president of Red Bull Canada, to its special advisory committee

He will champion the company’s Novoformulations-branded delivery systems for the pharmaceutical, nutraceutical and psychedelic medicine industries

Champignon Brands Inc. - Champignon Brands Inc appoints Jim Bailey, the former president of Red Bull Canada, to its special advisory committee
Bailey was instrumental in launching the Red Bull brand in Canada and growing the business to $150M in annual revenue

Champignon Brands Inc (CSE:SHRM) (OTCMKTS:SHRMF) has appointed Jim Bailey, the former president of Red Bull Canada, to its special advisory committee.

Vancouver-based Champignon said Bailey will champion the marketing, distribution and commercialization of the company’s Novoformulations-branded novel delivery systems for the pharmaceutical, nutraceutical and psychedelic medicine industries. 

The group noted that Bailey also previously served as the global chief marketing officer for Merrell Outdoors, overseeing both product and consumer marketing with annual revenues of US$600 million. 

Prior to his tenure at Merrell, Bailey served as president of Red Bull Canada, playing an instrumental role in launching the Red Bull brand in Canada and growing the business to $150 million in annual revenue with over 300 employees nationwide.

READ: Champignon Brands inks blockbuster deal to roll out network of psychedelic medicine clinics in North America

“I am very excited to be part of a company that is leading the way in finding alternative solutions to traditional pharmaceuticals with science-based research and functional products,” Bailey said in a statement Thursday. 

“My background in heavily regulated industries coupled with my experience in the CPG space provides a great compliment to an already talented and experienced advisory board.”

Novoformulations, a 100%-owned subsidiary of Champignon, is presently working with ketamine, anaesthetics and adaptogenics, as well as a host of pharmaceuticals and natural molecules at a purpose-built good manufacturing practice (GMP) and pharmaceutical (DIN) licensed facility in Quebec. 

Champignon said the subsidiary is actively formulating, developing and working to commercialize bioavailable delivery platforms, including transdermal (topical), intranasal and sublingual. 

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Champignon Brands Inc.

Price: 0.89 CAD

CSE:SHRM
Market: CSE
Market Cap: $70.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Champignon Brands Inc. named herein, including the promotion by the Company of Champignon Brands Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Champignon Brands charts course for success with acquisitions and a name change

Champignon Brands (CSE: SHRM- OTCQB: SHRMF) CEO Dr Roger McIntyre joined Steve Darling from Proactive Vancouver with news the company is changing its name to Apotheosis, which means the high point of development. McIntyre discusses the thinking behind the change, plus acquisitions and other...

on 22/6/20

2 min read